Sharat Israni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sharat Israni has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Abrar Mesbah
CoVAR
1 shared publication - Aleksandra Foksinska
Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham
1 shared publication - Andrew Crouse
Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham
1 shared publication - Andrew I. Su
The Scripps Research Institute
1 shared publication Arun Sridhar
University of Washington, Seattle, Washington
1 shared publicationBharat Vijay
AmberTag Inc, Milpitas, California
1 shared publication
Latest Publications
- Open Access
- 9 July 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (7) , e70284
Announcing the Biomedical Data Translator: Initial Public Release
The growing availability of biomedical data offers vast potential to improve human health, but the complexity and lack of integration of these datasets often limit their utility. To address this, the Biomedical Data Translator Consortium has developed an open‐source knowledge graph–based system—Translator—designed to integrate, harmonize, and make inferences over diverse biomedical data sources. We announce here Translator's initial public release and provide an overview of its architecture, standards, user interface, and core features. Translator employs a scalable, federated, knowledge graph framework for the integration of clinical, genomic, pharmacological, and other biomedical knowledge sources, enabling query retrieval, inference, and hypothesis generation. Translator's user interface is designed to support the exploration of knowledge relationships and the generation of insights, without requiring deep technical expertise and gradually revealing more detailed evidence, provenance, and confidence information, as needed by a given user. To demonstrate Translator's application and impact, we highlight features of the user interface in the context of three real‐world use cases: suggesting potential therapeutics for patients with rare disease; explaining the mechanism of action of a pipeline drug; and screening and validating drug candidates in a model organism. We discuss strengths and limitations of reasoning within a largely federated system and the need for rich concept modeling and deep provenance tracking. Finally, we outline future directions for enhancing Translator's functionality and expanding its data sources. Translator represents a significant step forward in making complex biomedical knowledge more accessible and actionable, aiming to accelerate translational research and improve patient care.
- 9 July 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (7) , e70284
Open AccessAnnouncing the Biomedical Data Translator: Initial Public Release
The growing availability of biomedical data offers vast potential to improve human health, but the complexity and lack of integration of these datasets often limit their utility. To address this, the Biomedical Data Translator Consortium has developed an open‐source knowledge graph–based system—Translator—designed to integrate, harmonize, and make inferences over diverse biomedical data sources. We announce here Translator's initial public release and provide an overview of its architecture, standards, user interface, and core features. Translator employs a scalable, federated, knowledge graph framework for the integration of clinical, genomic, pharmacological, and other biomedical knowledge sources, enabling query retrieval, inference, and hypothesis generation. Translator's user interface is designed to support the exploration of knowledge relationships and the generation of insights, without requiring deep technical expertise and gradually revealing more detailed evidence, provenance, and confidence information, as needed by a given user. To demonstrate Translator's application and impact, we highlight features of the user interface in the context of three real‐world use cases: suggesting potential therapeutics for patients with rare disease; explaining the mechanism of action of a pipeline drug; and screening and validating drug candidates in a model organism. We discuss strengths and limitations of reasoning within a largely federated system and the need for rich concept modeling and deep provenance tracking. Finally, we outline future directions for enhancing Translator's functionality and expanding its data sources. Translator represents a significant step forward in making complex biomedical knowledge more accessible and actionable, aiming to accelerate translational research and improve patient care.
- Open Access
- 1 July 2025
- Published by Elsevier in The Journal of Precision Medicine: Health and Disease
- Vol. 3
Precision medicine: Crossing the biomedical scales with AI
- 1 July 2025
- Published by Elsevier in The Journal of Precision Medicine: Health and Disease
- Vol. 3
Open AccessPrecision medicine: Crossing the biomedical scales with AI
- Open Access
- 27 September 2022
- Published by Elsevier in Cardiovascular Digital Health Journal
- Vol. 3 (6) , 263-275
Emerging role of artificial intelligence in cardiac electrophysiology
- 27 September 2022
- Published by Elsevier in Cardiovascular Digital Health Journal
- Vol. 3 (6) , 263-275
Open AccessEmerging role of artificial intelligence in cardiac electrophysiology